Reference change values of six biochemical quantities (P2-microglobulin, neopterin, adenosine deaminase and immunoglobulins IgA, IgG and IgM) have been established in asymptomatic human immunodeficiency virus (HIV)-infected patients following the method described by Harris and Yasaka in 1983. Patients included in the evaluation were classified as AI, A2 or A3 according to the classification of the Centers for Disease Control (CDC) (January 1993). All patients were followed-up quarterly, with a minimum of four samples each available for statistical analysis. The main objective of this paper was to study whether differences found to be greater than calculated reference change values could predict clinical or immunological worsening in patients' status. Retrospective analysis was made in asymptomatic patients (n = 256) included in an HIV infection protocol carried out in our hospital. Of these patients, 179 showed clinical or immunological worsening during the study period and 77 maintained their clinical and immunological status.
INTRODUCTION
Infection with human immunodeficiency virus (HIV) leads to a progressive loss of immune system function, ultimately leading to opportunistic infections and malignancies of the acquired immunodeficiency syndrome (AIDS). Several cohort studies have provided some insight Correspondence: Cecilia Martinez-Bni. E-mail: incortes@sendanet.es into the prediction of rate of disease progression, utilizing both clinical and laboratory parameters. The use of clinical criteria to predict disease progression is relatively insensitive and less accurate than laboratory markers, which are better established and more responsive to the effects of antiretroviral therapies. Several recent studies indicate a strong correlation between the slope of CD4 cell count decline and a rapid progression of HIV disease.':" Other markers (T cell and B cell activation markers, antibodies to HIV, direct virological markers) that can predict progression of HIV infection have also been described.V In our study, biochemical markers that have been described as predictors of progression of HIVinfection, such as serum P2-microglobulin7-11 and neopterin,12,13 have been evaluated. Other biochemical markers of HIV infection such as immunoglobulins'v!? and adenosine deaminase," although not yet so well established as having prognostic significance in HIV infection, have also been evaluated.
P2-Microglobulin forms the light chain of the class I major histocompatibility complex antigens that are present on the surface of most nucleated cells. It is shed into the serum of patients infected by HIV and may reflect lymphocyte turnover.'? Its levels correlate inversely with the rate of decline of CD4 + T cells. 20 Neopterin is a metabolite of guanosine triphosphate produced by macrophages when stimulated by interferon-y. Elevated serum levels of neopterin have been reported in conditions involving activation of cellular immunity." Longitudinal studies have revealed that neopterin levels correlate with disease progression. 22, 23 Serum immunoglobulin concentrations also increase in asymptomatic HIV infection, as a result of B cell activation. Spontaneous secretion of immunoglobulins of various classes tends to correlate negatively with CD4+ T cells.P", In late-stage HIV infection, serum concentrations of immunoglobulins may decrease.
Adenosine deaminase is a purine enzyme that catalyses the deamination of adenosine and other adenine nucleoside analogues to inosine, and is found in most human tissues. Its physiological role appears particularly relevant in lymphoid cells. AIDS is characterized by severe impairment of T cell functions and cellular immune response, and high enzyme activity is associated with both asymptomatic and symptomatic HIV disease."
The two main objectives of this study are: (I) to establish the difference between two consecutive measurements (critical value) of a given marker (P2-microglobulin, neopterin, adenosine deaminase and 19A, IgG and IgM) in asymptomatic HIV-infected patients, that could not be attributed either to analytical or to intraindividual variability; then, assuming that the difference found, in terms of concentration, is an indicator of a change in the immunological and clinical status of the patient, (2) to study whether Ann Clin Biochem 1999: 36 differences found to be greater than critical values could predict worsening in patients' status. A retrospective analysis of asymptomatic patients included in the HIV infection protocol was carried out to establish the sensitivity and specificity of this proposed procedure.
MATERIALS AND METHODS

Patients
HIV-infected patients followed-up in our hospital were included in this evaluation. A protocol for monitoring HIV infection has been carried out in our biochemistry department together with the internal medicine department since June 1991. According to this protocol, HIV-infected patients are investigated at regular periods of 3--4months. At each time point, patients undergo a clinical examination, recording Centers for Disease Control (CDC) staging, other clinical manifestations related or unrelated to HIV infection, and weight; antiretroviral therapy is considered. A blood analysis is requested for haematological quantities such as haemoglobin, totalleucocytes, total lymphocytes and subsets of CD4 and CD8 lymphocytes, platelets and erythrocyte sedimentation rate, as well as biochemical quantities such as urea, creatinine, cholesterol, triglycerides, aminotransferases (aspartate aminotransferase and alanine aminotransferase), y-glutamyltranspeptidase, alkaline phosphatase, lactate dehydrogenase, p2-microglobulin, neopterin, adenosine deaminase and IgA, IgG and IgM.
All patients included in this protocol who were classified as stages AI, A2 or A3 (CDC, January 1993) were considered when calculating reference change values for these biochemical markers. Only patients followed-up regularly (3-4 months) at least four times were selected (AI n = 67, A2 n = 63, A3 n = 35). The stability of each patient's status was confirmed by checking clinical and analytical parameters.
After calculating reference change values, all regularly controlled, initially asymptomatic patients included in the protocol were evaluated (n = 256) in order to establish the relation between the behaviour of these markers and the progression of the disease.
Criteria
Worsening in asymptomatic patients can be attributed either to clinical or to immunological progression.
According to the 1993 CDC classification, people suffering from HIV disease can be f3rMicroglobulin and immunoglobulins in HIV 603 classified into different categories according to clinical manifestations and CD4 cell counts. Unfortunately, this classification is not free of ambiguities. Variations in CD4 cell counts near the decision points of the classification, for example, can lead to frequent change from one stage to another. For this reason, and for practical purposes, we were obliged to establish some criteria when defining worsening in a patient's status, as listed below:
Criteria defining clinical worsening:
• Constitutional symptoms (weight loss > 10%, fever or diarrhoea > I month). • Infections -opportunistic or not -and malignancies which place individuals in stages IV-C2, IV-CI or IV-D of the 1986 CDC classification.
Criteria defining immunological worsening:
• False negatives: patients with worsening but without biochemical detection. A minimum period of 12 months free of biochemical detection was required before worsening. • True negatives: patients without worsening and without biochemical detection. A minimum period of 12 months was required after inclusion in the protocol.
Statistical methods
A reference change is defined as the difference between two consecutive test results in an individual that is statistically significant in a given proportion of all similar persons. The method described by Harris and Yasaka-" was used to state reference change values. This method is based on the distribution of intraindividual variances, assuming that an adequate reference change can be the difference D, so that:
where U~i is the within-individual true variance of a difference between two consecutive measurements in individual i.
Provided that there is no serial correlation between two consecutive measurements in individual i, then U~i = 2uf and equation (1) can be written as: In order to arrive at one difference D for all individuals i in a population, one has to replace the intraindividual crf by a constant, so that D is a significant difference (at one-sided level of maximally 5%) in a given proportion of the population of similar persons. For example, if uf is replaced by the median of its interindividual distribution, then it can be expected that D will be a significant change in a proportion of 50% of all individuals.
The within-subject variances were not distributed normally in our population. For this reason, within-subject variances were transformed to their logarithmic values, thus obtaining a log-normal Biochemical detection was equivalent to any increase in the concentration of any of the biochemical markers included in a combination of markers, greater than calculated critical values.
• True positives: patients with differences between two consecutive measurements greater than critical values (biochemical detection) and with evidence of worsening in their status. In this case, no maximum or minimum period of time was considered. • False positives: patients with differences greater than critical values without worsening. A minimum period of 12 months was required after biochemical detection.
Definitions
These two criteria were taken into account independently of absolute CD4 cell counts. Only patients with absolute CD4 cell counts within reference values (70Q-lI00 x 10 6 cellsfL), although following previous immunological criteria, were considered as patients with no evidence of progression.
Patients undergoing antiretroviral treatment with clinical or immunological progression were not excluded.
• Decline in absolute CD4 cell counts > 30%
in a period of 3 months (two consecutive analytical controls), maintained until next control. • Decline in absolute CD4 cell counts> 50% in a period of 6-12 months.
distribution. Afterwards, and assuming lognormality, robust estimates of the mean and variance of the logarithms of observed withinsubject variances were obtained. The estimate of the mean of the logarithms was converted to its counterpart in original units, mean (s1), using a standard formula relating the mean of a lognormal variable to the mean of its logarithm:
Samples
Blood samples were collected in glass tubes and allowed to clot for 2 h at room temperature. Once centrifuged, serum samples were immediately separated from cells and protected from light. Aliquots for analysis of these quantities were frozen until analysis, at -80°C. where exp[ ] denotes the exponential function of the quantity within brackets.
In the case of establishing a significant change (equation 3) in a proportion other than 50% of all individuals, the empirical distribution of s1 should be considered to quantify the corresponding proportion of the population in which the calculated value for D was expected to be a significant difference. This standard deviation should be included in the formula, together with its corresponding z value.
The mean of s2 has been chosen in equation (3) because the~ignificant change D is established in a proportion of at least 50% of all individuals.
Normality of variance distributions was checked by graphical methods.F Outliers were eliminated as stated by Natrella.P Statistically significant differences for intraindividual variances between groups of treated versus groups of untreated patients were studied by analysis of variance (ANOVA). 
RESULTS
Analytical imprecision
Coefficients of variation for between-run imprecision are listed in Table I .
ANOVA for intra-individual variances
In all stages considered (A I, A2 and A3) there were some patients undergoing antiretroviral therapy. Statistically significant differences for intraindividual variances between groups of treated versus untreated patients in each CDC stage were studied by means of an ANOVA analysis, for all biochemical markers evaluated. As no statistically significant differences were found, patients with and without antiretroviral therapy were considered at all clinical stages.
Normality of distribution of variances
Intra-individual variances did not fit a normal distribution. For all biochemical quantities, once intra-individual variances were transformed to their logarithmic values, the normality of their distribution was obtained and checked by means of the graphical method mentioned above.
Reference change values Mean, standard deviation, minimum and maximum, and critical or reference change values are given in Table 2 for p2-microglobulin, neopterin and adenosine deaminase, and in Table 3 for IgA, IgG and IgM. 
16·69 11·52 5·02-56,61 10·48 Adenosine dearninase (U/L, 37"C)
37-42 13·05 12'5-77-9 14·24 Table 5 lists combinations of two, three, four and five markers that show the best sensitivity, as well as sensitivity and specificity, obtained from the combination of six markers. Using the combination that includes the six biochemical markers evaluated, clinical or immunological worsening was detected in 169 of 179 patients. Only 10 patients did not show any progression in biochemical markers greater than reference values calculated during a minimum period of 12 months, before worsening (Table 6 ). Biochemical detection was found in 29 of 77 patients without worsening (a period of 12 months had elapsed since detection). No biochemical detection or worsening was detected in 48 patients.
The sensitivity of the proposed procedure with a combination of six markers was 94-4% and specificity was 62·3%.
RCV Range Mean SD CDC stage
DISCUSSION
An asymptomatic HIV-infected patient, as all patients included in this evaluation, who shows an increase between two consecutive measurements of a quantity greater than the reference change value calculated for this marker, independently of the absolute value of its previous concentration, can be assumed to be undergoing progression of the clinical or immunological
CDC stage
Mean SD Range RCV
2·13 1·09 0,57-5,00 0·75 
Retrospective analysis
Of 256 patients re-evaluated, 179 showed clinical or immunological worsening during the study period, and 77 maintained their clinical and immunological status. Markers were evaluated independently of each other as being useful for predicting progression, establishing their own sensitivity and specificity ( disease process. This information may be helpful for the clinician in that it may be predicting a worsening in a patient's status.
In the retrospective analysis, when markers were considered independently of each other, f32micro globulin showed the greatest sensitivity (43'0%) to detect clinical or immunological worsening, followed by neopterin (41'9%). Adenosine deaminase showed the lowest sensitivity (21·8%) and specificity (84'4%).
Adding another marker to f32-microglobulin, the best combination of two markers was found to be f32-microglobulin and IgA (sensitivity of 67'0%). Sensitivity increased to 80-4% when IgG was added to f32-microglobulin and IgA.
With four markers, the greatest sensitivity (88'8%) was obtained by adding neopterin to the previous combination of three markers. The combination of f32-microglobulin and IgA, IgG and IgM yielded a sensitivity of 84·9%.
Finally, when adding IgM to previous markers (f32-microglobulin, IgA, IgG and neopterin), the sensitivity was 92·2%.
When considering increases in any of the six markers evaluated, the retrospective analysis yielded a sensitivity of 94-4% and a specificity of 62·3%. Critical differences or reference change values (for the combination of six markers) based on the use of percentiles (60th, 70th, 80th and 90th) of observed within-subject variances were also studied (results not shown). The reference change values obtained with the use of the mean of observed within-subject variances offered greater sensitivity (a smaller critical difference); alternatively, with increasing percentiles, specificity was greater. By varying the cut-off point for D, one could balance the sensitivity against the specificity. Nevertheless, as the main interest lies in establishing a cut-off value for D which confers the greatest sensitivity, the mean of sf has been considered in equation (3).
Furthermore, specificity decreases as the number of markers included in the combination increases. Nevertheless, it is preferable to increase sensitivity, as the main important feature is to detect the maximum number of patients who may progress to advanced stages of HIV infection.
It should be pointed out that, when considering increases of only a single marker, increases in adenosine deaminase concentration allowed a greater proportion of false positives (n = 5) than true positives (n = 4) to be detected. This was not the case for any of the other five markers Ann Clin Biochem 1999: 36 studied. We then considered the possibility of discarding adenosine deaminase as a useful tool for detecting progression of disease, obtaining a sensitivity and a specificity of 92·2% and 68,8%, respectively.
CONCLUSION
For almost all biochemical markers evaluated, concentration mean values increased as CD4 lymphocyte counts declined: from Al (CD4 cells > 500 x 10 6/L), to A2 (CD4 cells between 200 and 500 x 10 6 /L) to A3 (CD4 cells < 200 x 10 6 /L).
Furthermore, the interval of concentrations of these markers was greater for advanced stages (A2 and A3) than for AI. Reference change values calculated showed a similar trend: that is, the greatest values were found for A3 and the lowest for A I.
It was also observed that reference change values for a given quantity are not the same for all CDC stages studied. For this reason, increases cannot be considered in the same way in all patients. Critical values should therefore be established and taken into account when evaluating patients in different CDC stages, as they are helpful in predicting progression of HIV infection and worsening in patients' status. Clinical actions derived from these results can be directed towards therapeutic intervention, as initiation of antiretroviral treatment, or modification of a previous antiretroviral treatment (type, dose, monotreatment or combination of antiretrovirals), or prophylactic intervention against most life-threatening infections that can affect HIV-infected patients.
The retrospective study showed that: (I) combining the six markers evaluated, a large majority (94%) of asymptomatic patients showing a worsening in their clinical or immunological status is detected by means of reference change values calculated; (2) adenosine deaminase appears to be of little value in predicting disease progression in HIV infection as this quantity allowed detection of a greater proportion of false positives than true positives; (3) f32micro globulin was the biochemical marker with greatest sensitivity; (4) if a combination of markers were to be recommended, the best combination, on the basis of analytical practicability, availability and sensitivity, would be f32microglobulin and IgA, IgG and IgM. This combination yielded a sensitivity of 84·9% and a specificity of 74·0% in predicting clinical or immunological worsening of patients' status.
